5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

SMS Pharmaceuticals Ltd.

•
smspharma.comBSE: 532815NSE: SMSPHARMA
Market Cap₹ 4,348 Cr.
Current Price
High / Low₹ 469 / 242
Stock P/E42.5
Book Value₹ 86
Price to Book3.02
Dividend Yield0.09 %
ROCE12.6 %
ROE11.9 %
Face Value₹ 1

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Promoters have been increasing their shareholding - up 3.4pp over 2 years
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.28x)
  • Company has a consistent dividend-paying track record
  • Company maintains a comfortable, low leverage position

CONS

  • Company has a low return on capital employed of 9.4%
  • Company has a low return on equity of 7.6% over last 3 years
  • Free cash flow has been persistently negative
  • Operating margins have contracted to 16.4% from 21.6%
  • Growth is decelerating - 3Y profit CAGR (-0.2%) trails the 5Y trend (15.6%)

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.SMSPHARMA464.3042.464348.260.0920.912.04206.975.5712.5520.13
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
135167161246164197173248196242210238207
109139132212131165140207157194167198182
Operating Profit26282934343133413948444025
OPM %19.34%16.69%17.95%13.68%20.38%15.99%19.16%16.44%20.08%19.95%20.74%16.77%12.30%
1112112111432
Interest6666554566656
Depreciation888889991010101010
Profit before Tax13151722222022292434312728
Tax %30.52%20.51%25.65%26.17%25.01%29.07%23.89%29.58%23.18%26.18%25.58%22.53%25.09%
Net Profit00001614182020252332721
1.101.391.362.041.951.672.152.402.312.842.593.582.23

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
603438463465412563520522709783898
514363369375332442405468593644740
Operating Profit897593908012111555117139157
OPM %14.79%17.15%20.17%19.39%19.43%21.51%22.05%10.45%16.46%17.76%17.53%
41235355469
Interest1716151212111922241923
Depreciation1919201922223232323440
Profit before Tax5642606251916856692120
Tax %26.00%14.35%32.97%33.52%35.60%33.09%0.90%27.39%25.57%27.01%24.95%
Net Profit423640413361684496790
EPS4.833.373.754.733.737.397.35-0.835.897.80—
Dividend Payout %4.14%5.94%6.67%5.28%6.70%4.06%4.08%-35.98%6.80%5.13%—

COMPOUNDED SALES GROWTH

10 Years:
—
5 Years:
14%
3 Years:
15%

COMPOUNDED PROFIT GROWTH

10 Years:
—
5 Years:
17%
3 Years:
4%

STOCK PRICE CAGR

10 Years:
18%
5 Years:
23%
3 Years:
56%
1 Year:
54%

RETURN ON EQUITY

10 Years:
12%
5 Years:
11%
3 Years:
8%
Last Year:
12%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2026

Sep 22

₹ 0.40

Rs.0.4000 per share(40%)Final Dividend

2026

Sep 22

₹ 0.40

Rs.0.4000 per share(40%)Final Dividend

2025

Sep 22

₹ 0.40

Rs.0.4000 per share(40%)Final Dividend

2024

Sep 23

₹ 0.40

Rs.0.4000 per share(40%)Final Dividend

2023

Sep 22

₹ 0.30

Rs.0.3000 per share(30%)Final Dividend

2022

Sep 22

₹ 0.30

Rs.0.3000 per share(30%)Final Dividend

2021

Sep 22

₹ 0.30

Rs.0.3000 per share(30%)Final Dividend

2018

Sep 11

₹ 0.25

Rs.0.2500 per share(25%)Dividend

2017

Sep 20

₹ 0.20

Rs.0.2000 per share(20%)Dividend

2016

Sep 22

₹ 0.20

Rs.0.2000 per share(20%)Final Dividend

2015

Sep 22

₹ 0.20

Rs.2.0000 per share(20%)Dividend

2026

Aug 3

₹ 0.40

Rs.0.4000 per share(40%)Final Dividend

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Equity Capital8888888889
285246276313340402462452499615
204149146144157254262253236264
Trade Payables84673948446573107151114
7432455967996959154171
Total Liabilities6565025155726178288758801,0491,173
370290279281280457438412437533
Capital Work in Progress13881842711333035
21292827262722111112
11393107136129138251223234285
00000000236203
Cash & Bank1512131510414773642
1247079941301591061936464
Total Assets6565025155726178288758801,0491,173

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
838343635210660275082
Cash from Investing-97-39-17-35-43-152-27-30-52-123
Cash from Financing44-33-15-13-292-12-323147
9102-5316-39295

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
64.6764.6764.6766.2666.2668.0768.0768.0768.07
0.180.520.310.080.030.280.040.310.65
2.132.552.552.433.032.883.213.012.83
Government0.000.000.000.000.000.000.000.000.00
33.0332.2632.4731.2230.6728.7828.6928.6128.45

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-10
Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-10 - SMS Pharmaceuticals Limited has informed the Exchange about Schedule of meet

2026-09-05
Copy of Newspaper Publication

2026-09-05 - SMS Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

2026-09-04
Updates

2026-09-04 - SMS Pharmaceuticals Limited has informed the Exchange regarding 'Letter to Shareholders regarding Annual Report'.

2026-09-04
Updates

2026-09-04 - SMS Pharmaceuticals Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report for the financial year 2025-26'.

2026-09-04
Shareholders meeting

2026-09-04 - SMS Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 29, 2026

2026-09-02
Credit Rating

2026-09-02 - SMS Pharmaceuticals Limited has informed the Exchange about Credit Rating

2026-08-29
Copy of Newspaper Publication

2026-08-29 - SMS Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-27
Revised Record date

2026-08-27 - SMS Pharmaceuticals Limited had intimated the 16-Sep-2026 as the record date. The Company has now informed the Exchange that the Record date has been revised to 22-Sep-2026 for the purpose of DI.

2026-08-27
General Updates

2026-08-27 - SMS Pharmaceuticals Limited has informed the Exchange about change in date of 38th Annual General Meeting

News

Recent coverage and analyst commentary for SMSPHARMA

Loading news…

🤖

AI Stock Analyst

SMS Pharmaceuticals Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login